Cancelli Iacopo, Cadore Italo Pittaro, Merlino Giovanni, Valentinis Luca, Moratti Ugo, Bergonzi Paolo, Gigli Gian Luigi, Valente Mariarosaria
Neurology and Neurophysiopathology Unit, S. Maria della Misericordia Hospital and Udine University Hospital, DPMSC, Udine, Italy.
J Clin Neurophysiol. 2006 Oct;23(5):421-5. doi: 10.1097/01.wnp.0000218991.99714.ee.
Sensory gating is defined as the brain's ability to inhibit repetitive and irrelevant incoming sensory stimuli and is supposed to be related to cholinergic transmission. Indeed, Alzheimer's disease (AD) is characterized by a cholinergic deficit that is believed to be involved in cerebral cortex hyperexcitability and short latency afferent inhibition deficit. Therefore, a sensory gating deficit may be supposed present in AD within the frame of cortex hyperexcitability and loss of cortex modulation of sensory inputs. The authors investigated whether a sensory gating deficit may be present in AD and whether this deficit may be related to the presence of neuropsychiatric symptoms (NPS) and reversed by donepezil treatment. Sensory gating was evaluated using a paired-stimulus auditory P50 event-related potential paradigm. Eighteen drug-naïve probable AD patients (mean age 76.1 years; SD 5.6 years; 13 females and 5 males) and 15 healthy elderly controls (mean age 74.2 years; SD 5.4 years; 10 females and 5 males) were recruited. Sensory gating was evaluated in AD patients before starting therapy and after 1 and 3 months of donepezil treatment. Auditory P50 sensory gating was impaired in AD patients but no correlation was found between gating deficit and NPS. Moreover, AD patients displayed increased P50 amplitude when compared with healthy elderly subjects. Donepezil treatment did not improve P50 sensory gating in AD patients but decreased P50 amplitude. Patients with AD displayed an augmented P50 amplitude, in accordance with previous studies, suggesting increased cortex excitability. Donepezil does not affect P50 sensory gating but reduces P50 amplitude. Donepezil may induce P50 amplitude reduction by means of enhanced dopamine release. Indeed, it has been demonstrated that donepezil induces dopamine release "in vitro." The findings suggest that AD patients have a sensory gating impairment but the link with both NPS and the cholinergic deficit is doubtful.
感觉门控被定义为大脑抑制重复性和不相关传入感觉刺激的能力,并且被认为与胆碱能传递有关。事实上,阿尔茨海默病(AD)的特征是胆碱能缺陷,据信这与大脑皮层的过度兴奋和短潜伏期传入抑制缺陷有关。因此,在大脑皮层过度兴奋和感觉输入的皮层调节丧失的框架内,可以推测AD患者存在感觉门控缺陷。作者研究了AD患者是否存在感觉门控缺陷,以及这种缺陷是否与神经精神症状(NPS)的存在有关,以及多奈哌齐治疗是否能逆转这种缺陷。使用配对刺激听觉P50事件相关电位范式评估感觉门控。招募了18名未服用过药物的可能患有AD的患者(平均年龄76.1岁;标准差5.6岁;13名女性和5名男性)和15名健康老年对照者(平均年龄74.2岁;标准差5.4岁;10名女性和5名男性)。在AD患者开始治疗前以及多奈哌齐治疗1个月和3个月后评估感觉门控。AD患者的听觉P50感觉门控受损,但门控缺陷与NPS之间未发现相关性。此外,与健康老年受试者相比,AD患者的P50波幅增加。多奈哌齐治疗并未改善AD患者的P50感觉门控,但降低了P50波幅。与先前的研究一致,AD患者表现出P50波幅增加,提示大脑皮层兴奋性增加。多奈哌齐不影响P50感觉门控,但降低P50波幅。多奈哌齐可能通过增强多巴胺释放来降低P50波幅。事实上,已经证明多奈哌齐在“体外”可诱导多巴胺释放。这些发现表明AD患者存在感觉门控损害,但与NPS和胆碱能缺陷之间的联系尚不确定。